Medtronic Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDT research report →
Range $83 – $120
Price Chart
About the company
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software.
- CEO
- Geoffrey Straub Martha
- IPO
- 1973
- Employees
- 95,000
- HQ
- Galway, GA, IE
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive multi-month uptrend and remains above its 200-day average of 88.26, with the 50-day at 93.72 also trending higher. It sits near the top of its 52-week range, showing a mature advance rather than a deep breakout setup.
Street sentiment is constructive: consensus sits at Buy with a 97.73 median target and 105 average target, both below the current share price. Recent actions were mixed but still supportive, with several firms reiterating positive stances while Barclays initiated at Equal Weight and BTIG trimmed its target to 99.
The earnings profile remains dependable, with 7 straight EPS beats and the last four surprises ranging from 0.6% to 4.3%. Next quarter is expected at $1.34 EPS, up from the prior run-rate, so shareholders should watch whether Medtronic can keep the beat streak alive and support the higher full-year path.
Recent insider activity leans to net selling, led by discretionary sales from the CEO and an EVP, while several officer awards and in-kind items look routine rather than signal-rich. The pattern does not show broad insider accumulation, so the market will likely focus more on execution than insider conviction.
Profitability is solid, with a 65.3% gross margin, 20.1% operating margin, and 13.9% net margin. Growth is healthy too, with revenue up 13.7% year over year and earnings up 40.7%, while free cash flow reached $9.23 billion for fiscal 2026.
Medtronic screens as a large-cap, lower-beta defensive name with a premium quality profile versus many medtech peers. At 18.6x earnings, it trades at a reasonable valuation for a company with strong cash generation and steady execution.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $127.84B
- P/E
- 25.08
- Fwd P/E
- 16.72
- PEG
- 2.02
- P/S
- 3.49
- P/B
- 2.61
- EV/EBITDA
- 15.33
- Div Yield
- 2.80%
- Gross Margin
- 66.69%
- Op Margin
- 18.08%
- Net Margin
- 13.93%
- ROE
- 10.60%
- ROIC
- 6.44%
Latest fiscal year · YoY change
- Revenue
- $36.36B+8.4%
- Gross Profit
- $23.64B+7.9%
- Op Income
- $6.47B
- Net Income
- $4.80B+3.0%
- EPS
- $3.75+3.3%
- OCF Growth
- +4.1%
- FCF Growth
- +4.6%
- 52W High
- $106.33
- 52W Low
- $73.31
- 50D MA
- $94.45
- 200D MA
- $88.24
- Beta
- 0.57
- RSI (14)
- 54
- Avg Volume
- 16.53M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medtronic posted a strong Q1 with $9.8 billion in revenue, $1.45 adjusted EPS, and 13.7% organic growth, then raised full-year organic sales and EPS guidance.· September 1, 2026
- Q1 revenue was $9.8 billion and adjusted EPS was $1.45, both above expectations, with organic growth of 13.7%.
- Management said the quarter benefited from a 53rd week, estimated to add about $570 million and 670 basis points to organic revenue growth.
- Core growth engines were broad: CRM grew 15%, CST 13%, Surgical 9%, Pelvic Health 15%, and CAS 88%.
- Full-year FY27 guidance was raised to 7.25%–7.75% organic revenue growth and $5.94–$6.00 adjusted EPS; Q2 organic growth is expected at roughly 6%.
- Management emphasized continued investment in high-growth areas, including CAS, robotics, structural heart, renal denervation, and tuck-in M&A.
Revenue was $9.8 billion, up 13.7% reported and organically. Adjusted EPS was $1.45, which Thierry said was $0.06 above the midpoint of guidance and Street expectations. Adjusted gross margin was 65.2%, up 10 basis points year over year, and adjusted operating margin was 23.7%, up 10 basis points year over year; adjusted operating profit was $2.3 billion, up 15% year over year. Geography was nearly 16% growth in the U.S. and 12% internationally. Management raised FY27 organic revenue growth guidance to 7.25%–7.75% from prior guidance and raised FY27 adjusted EPS guidance to $5.94–$6.00. For Q2, the company expects about 6% organic revenue growth and EPS of $1.32–$1.34. FX is expected to be a roughly $50 million to $150 million headwind for the full year and about $25 million to $75 million in Q2. Management also said full-year FY27 operating profit should grow approximately 10% with operating margin expanding about 50 basis points. The extra week contributed approximately $570 million, or 670 basis points, to total organic enterprise revenue growth.
Geoff Martha characterized Q1 as a strong start and a proof point that Medtronic’s strategy is translating into results. He highlighted broad-based strength across CRM, CST, Surgical and newer growth platforms such as CAS, Symplicity, Altaviva and Hugo, and he said the company is ‘doubling down’ on high-growth areas through innovation, ecosystem building and targeted investments. His tone was confident and constructive, while also stressing discipline and continued execution rather than declaring victory.
Thierry Pieton focused on margin discipline and the drivers behind the quarter’s upside. He said gross margin was 65.2%, helped by 30 basis points from pricing and 50 basis points from cost-out, partially offset by 50 basis points of unfavorable mix, mainly from diabetes and CAS, while tariffs were a slight headwind and FX was roughly neutral. He also said adjusted SG&A was 32.4% of revenue, R&D was 7.9%, adjusted operating profit was $2.3 billion, and free cash flow conversion in Q1 was 70%, with a path to 80%. On capital allocation, he said the company has increased investment in innovation and M&A, and that the Cornerstone deal adds about $700 million of investment with some foregone interest this year and distribution benefits starting in FY28.
Analysts focused on how much of the upside came from CAS versus the rest of the portfolio, the rationale for the Cornerstone robotics agreement, diabetes separation timing, margin reinvestment, tariffs, and what the Charlotte investor meeting will cover. Management said the quarter’s breadth was broad-based, with several businesses beyond CAS contributing, and reiterated that CAS should grow more than 2.5x the market for the full year and more than 3x in Q2. On Cornerstone, management said it is a distribution/partnership deal that expands Medtronic’s global robotics portfolio rather than a sign of weakness in Hugo, and said it provides strategic optionality but no immediate acquisition plan. On diabetes, management said there is no change in separation timing; they will proceed when economics are optimal. They also said tariffs were nearly offset by refunds in Q1 but future refunds were not assumed in guidance.
The bull case from this call is that Medtronic is seeing stronger, broader execution across multiple businesses at once, not just one product cycle. Management sounded increasingly confident that CAS, Hugo, Altaviva, Ardian, Stealth AXiS and other platforms have meaningful runway, and they raised full-year guidance after a better-than-expected quarter.
The main risks raised were that some of the quarter’s growth was helped by the extra week, mix remains a drag from diabetes and CAS, and some businesses are expected to normalize later in the year. Management also flagged tougher CAS comps ahead, ongoing dependence on reimbursement and market development in Ardian, and the fact that tariffs and FX could still be headwinds even if Q1 was helped by refunds.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 1.28B
- Float Shares
- 1.28B
of shares held by institutions
2,214 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MDT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 24, 26 | Filing → |
| Rich McCormickHouse · GA06 | Sell | Jul 30, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | May 7, 25 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Aug 26, 24 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | May 15, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 20, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Dec 18, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Nov 13, 25 | Filing → |
| Rich McCormickHouse · GA06 | Buy | Nov 5, 25 | Filing → |
| Rich McCormickHouse · GA06 | Buy | Mar 15, 23 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Aug 14, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jun 27, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 128.96M | ▲ 1.89M |
| Blackrock, Inc. | 118.77M | ▲ 4.75M |
| Vanguard Capital Management LLC | 83.75M | ▼ 64.07K |
| State Street Corp | 65.99M | ▲ 2.59M |
| Vanguard Portfolio Management LLC | 34.30M | ▲ 242.98K |
| Geode Capital Management, LLC | 30.88M | ▲ 687.76K |
| Jpmorgan Chase & Co | 21.71M | ▼ 6.07M |
| Bank Of America Corp | 20.69M | ▼ 632.87K |
| Morgan Stanley | 19.22M | ▼ 222.36K |
| Franklin Templeton Inc | 18.22M | ▲ 666.32K |
| Massachusetts Financial Services Co | 18.09M | ▼ 1.78M |
| Deutsche Bank AG\ | 18.00M | ▼ 452.91K |
Held by 1,448 ETFs
Biggest fund positions in MDT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Marinaro Michael | other | 6,547 |
| Nov 2, 26 | Marinaro Michael | other | 42,994 |
| Nov 2, 26 | Marinaro Michael | other | 16,367 |
| Oct 15, 26 | Lofton Kevin E | other | 182 |
| Oct 15, 26 | Marinaro Michael | sell | 10,420 |
| Oct 15, 26 | Martha Geoffrey | sell | 50,000 |
| Sep 16, 26 | KIIL HARRY SKIP | sell | 1,483 |
| Sep 15, 26 | Blomquist Denise L. | other | 600 |
| Aug 20, 26 | Marinaro Michael | other | 1,084 |
| Aug 3, 26 | Blomquist Denise L. | other | 2,337 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDT coverage
Recent articles, reports, and earnings notes.

Medtronic (MDT): Reacceleration Driven by New Growth Platforms
Medtronic is shifting from a slow-growth story to an execution-led reacceleration, with broad-based Q1 strength across cardiovascular, neuroscience, and medical surgical. The stock earns a Buy as growth platforms like Affera, Hugo, and Micra support a fair value of $99.

Top Healthcare Dividend Stocks: Our 5 Picks for November 2026
Healthcare dividend stocks span insurers, distributors, diagnostics, medical devices, and branded medicines in this five-stock November 2026 countdown.

MiniMed Group IPO: The Bull and Bear Case for a Diabetes Carve-Out
MiniMed Group, Inc. Common Stock When Issued is expected to list on NASDAQ on 2026-10-01 under the symbol MMEDV. The price range has not been disclosed yet. The bull case is a global diabetes-tech platform with $3.102 billion in fiscal 2026 sales; the bear case is execution risk, heavy competition, and a float dominated by Medtronic.
Want a deeper read on MDT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
18,505 Shares in Medtronic PLC $MDT Bought by Banco Santander S.A.
defenseworld.net · Nov 20
Medtronic (NYSE:MDT) versus Lifeward (NASDAQ:LFWD) Head-To-Head Analysis
defenseworld.net · Nov 20
Ahead of Medtronic (MDT) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
zacks.com · Nov 19
Medtronic (MDT) Declines More Than Market: Some Information for Investors
zacks.com · Nov 18
4 High-Yield Healthcare Stocks Retirees Should Buy for December Income
247wallst.com · Nov 18
Should You Continue to Hold Medtronic Stock in Your Portfolio?
zacks.com · Nov 18
4 Dividend Stocks That Can Thrive Under a Democratic Congress
247wallst.com · Nov 18
Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
zacks.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice